Kevin Shan

848 total citations · 1 hit paper
19 papers, 596 citations indexed

About

Kevin Shan is a scholar working on Molecular Biology, Pharmacology and Pathology and Forensic Medicine. According to data from OpenAlex, Kevin Shan has authored 19 papers receiving a total of 596 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Pharmacology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Kevin Shan's work include Pharmacology and Obesity Treatment (3 papers), Multiple Sclerosis Research Studies (3 papers) and Eating Disorders and Behaviors (3 papers). Kevin Shan is often cited by papers focused on Pharmacology and Obesity Treatment (3 papers), Multiple Sclerosis Research Studies (3 papers) and Eating Disorders and Behaviors (3 papers). Kevin Shan collaborates with scholars based in United States, France and Canada. Kevin Shan's co-authors include Holly Maier, Éric Ravussin, Julie A. Mitchell, Joy E. Koda, Reshma Shringarpure, Christian Weyer, Steven R. Smith, Amy E. Halseth, Brandon Walsh and Andrés Yarur and has published in prestigious journals such as The Lancet, Gastroenterology and The FASEB Journal.

In The Last Decade

Kevin Shan

18 papers receiving 562 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

2023 190 citations William J. Sandborn, Séverine Vermeire et al. The Lancet profile →

Peers

Countries citing papers authored by Kevin Shan

Since Specialization

Citations

This map shows the geographic impact of Kevin Shan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Shan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Shan more than expected).

Fields of papers citing papers by Kevin Shan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Shan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Shan. The network helps show where Kevin Shan may publish in the future.

Co-authorship network of co-authors of Kevin Shan

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Shan. A scholar is included among the top collaborators of Kevin Shan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Shan. Kevin Shan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Associations of Central Arterial Stiffness With Brain White Matter Integrity and Gray Matter Volume in MRI Across the Adult Lifespan 2025 ·Journal of Magnetic Resonance Imaging ·Junyeon Won, Tsubasa Tomoto, Kevin Shan, Takashi Tarumi, Rong Zhang	1
2	Association of Blood Pressure With Brain White Matter Microstructural Integrity Assessed With MRI Diffusion Tensor Imaging in Healthy Young Adults 2024 ·Hypertension ·Junyeon Won, Pauline Maillard, Kevin Shan, (unknown), Danilo Cardim, David C. Zhu, Rong Zhang	5
3	Dynamic Expansion and Contraction of Multiple Sclerosis T2-Weighted Hyperintense Lesions Are Present below the Threshold of Visual Perception 2024 ·American Journal of Neuroradiology ·Darin T. Okuda, (unknown), Morgan McCreary, Kevin Shan, (unknown), (unknown), (unknown), (unknown), (unknown), Christine Lebrun‐Frénay	0
4	Generative artificial intelligence versus clinicians: Who diagnoses multiple sclerosis faster and with greater accuracy? 2024 ·Multiple Sclerosis and Related Disorders ·(unknown), Francisco J. Villalobos, Kevin Shan, (unknown), (unknown), Peter V. Sguigna, Kyle Blackburn, (unknown), (unknown), (unknown), (unknown), Morgan McCreary, Darin T. Okuda	6
5	Faster and better than a physician?: Assessing diagnostic proficiency of ChatGPT in misdiagnosed individuals with neuromyelitis optica spectrum disorder 2024 ·Journal of the Neurological Sciences ·Kevin Shan, (unknown), Morgan McCreary, (unknown), Francisco J. Villalobos, (unknown), (unknown), Peter V. Sguigna, Kyle Blackburn, (unknown), (unknown), (unknown), (unknown), Darin T. Okuda	1
6	Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies breakdown → 2023 ·The Lancet ·William J. Sandborn, Séverine Vermeire, Laurent Peyrin‐Biroulet, Marla C. Dubinsky, Julián Panés, Andrés Yarur, Timothy E. Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, (unknown), Michael Chiorean, Douglas C. Wolf, Bruce E. Sands, Geert D’Haens, Silvio Danese, Martina Goetsch, Brian G. Feagan	190
7	948 ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 2.5 YEARS OF POOLED SAFETY DATA FROM GLOBAL CLINICAL TRIALS 2023 ·Gastroenterology ·Séverine Vermeire, Laurent Peyrin‐Biroulet, Julián Panés, Miguel Regueiro, Paulo Gustavo Kotze, Aline Charabaty, Martina Goetsch, Kevin Shan, Joseph Wu, Aoibhinn McDonnell, John Woolcott, Silvio Danese	2
8	P207 Effects of fluconazole, gemfibrozil, and rifampin on the pharmacokinetics, safety, and tolerability of etrasimod 2022 ·Poster presentations ·Caroline Lee, (unknown), Yong Tang, Leonel Villa-Caballero, Kevin Shan, (unknown), John S. Grundy, Caroline Lee	4
9	S774 Pharmacokinetics, Safety, and Tolerability of Etrasimod: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Volunteers 2022 ·The American Journal of Gastroenterology ·(unknown), Yong Tang, Leonel Villa-Caballero, Kevin Shan, (unknown), John S. Grundy	1
10	968a: ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS 2022 ·Gastroenterology ·William J. Sandborn, Séverine Vermeire, Laurent Peyrin‐Biroulet, Marla C. Dubinsky, Julián Panés, Andrés Yarur, Timothy E. Ritter, Filip J. Baert, Sheldon Sloan, Fabio Cataldi, Kevin Shan, (unknown), Michael Chiorean, Douglas C. Wolf, Bruce E. Sands, Geert D’Haens, Silvio Danese, Martina Goetsch, Brian G. Feagan	6
11	Analogical Framing: How Policy Comparisons Alter Political Support for Health Care Reform 2020 ·American Politics Research ·Jason Barabas, (unknown), Kevin Shan	6
12	The apical membrane localization and trafficking of uromodulin (UMOD) is critically dependent on nonmuscle myosin II isoforms Myh9 and Myh10 in mouse thick ascending limb epithelial cells 2019 ·The FASEB Journal ·(unknown), (unknown), (unknown), Kevin Shan, (unknown), Kameswaran Surendran, Indra Chandrasekar	1
13	Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion 2018 ·Obesity Science & Practice ·Amy E. Halseth, Kevin Shan, Kye Gilder, (unknown), Lisette M. Acevedo, Ken Fujioka	22
14	Effect on Body Weight of Naltrexone/Bupropion in Overweight and Obese Participants with Cardiovascular Risk Factors in a Large Randomized Double-Blind Study 2017 ·Amy E. Halseth, Kevin Shan, Kye Gilder, John B. Buse	1
15	Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study 2017 ·Advances in Therapy ·Anna I. Guerdjikova, Brandon Walsh, Kevin Shan, Amy E. Halseth, Eduardo Dunayevich, Susan L. McElroy	37
16	Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity 2016 ·Obesity ·Amy E. Halseth, Kevin Shan, Brandon Walsh, Kye Gilder, Ken Fujioka	29
17	Effects of Pramlintide in Patients with Type 2 Diabetes Mellitus: An Analysis Using Daily Insulin Dose Tertiles 2014 ·Endocrine Practice ·Kathrin Herrmann, Kevin Shan, Steven C. Brunell, (unknown)	6
18	Pramlintide Improved Measures of Glycemic Control and Body Weight in Patients With Type I Diabetes Mellitus Undergoing Continuous Subcutaneous Insulin Infusion Therapy 2013 ·Postgraduate Medicine ·Kathrin Herrmann, Juan P. Frías, Steven V. Edelman, Karen Lutz, Kevin Shan, Steven Chen, David Maggs, Orville Kolterman	19
19	Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy 2009 ·Obesity ·Éric Ravussin, Steven R. Smith, Julie A. Mitchell, Reshma Shringarpure, Kevin Shan, Holly Maier, Joy E. Koda, Christian Weyer	259

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact